A
A. Corey
Researcher at Stanford University
Publications - 11
Citations - 577
A. Corey is an academic researcher from Stanford University. The author has contributed to research in topics: Monoclonal antibody & Tumor necrosis factor alpha. The author has an hindex of 8, co-authored 11 publications receiving 562 citations.
Papers
More filters
Journal ArticleDOI
Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers.
Ruth Plummer,Gerhardt Attard,Simon Pacey,L. Li,Albiruni Ryan Abdul Razak,Rebecca Perrett,Mary Barrett,Ian Judson,Stan B. Kaye,N. L. Fox,Wendy Halpern,A. Corey,Hilary Calvert,Johann S. de Bono +13 more
TL;DR: Lexatumumab was safe and well tolerated at doses up to and including 10 mg/kg every 21 days and was associated with sustained stable disease in several patients, and consistent with a two-compartment model with first-order elimination from the central compartment.
Journal ArticleDOI
A phase 1 study of mapatumumab (fully human monoclonal antibody to TRAIL-R1) in patients with advanced solid malignancies.
Sebastien J. Hotte,Hal W. Hirte,Eric Chen,Lillian L. Siu,Lyly H. Le,A. Corey,A. Iacobucci,M. Maclean,Larry Lo,N. L. Fox,Amit M. Oza +10 more
TL;DR: The tolerability and toxicity profile of ≥2 doses of mapatumumab administered i.v. in patients with advanced solid tumors is well tolerated and further evaluation of this TRAIL-R1 targeting agent is warranted.
Journal ArticleDOI
HGS-ETR1, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: Results of a phase 1 and PK study
Laura Q.M. Chow,S. G. Eckhardt,Daniel L. Gustafson,Cindy L. O'Bryant,S. Hariharan,Sami Diab,N. L. Fox,A. Corey,Kristin Padavic,M. Brown,Roger B. Cohen +10 more
TL;DR: This Phase 1 study assesses the safety, tolerability, pharmacokinetics (PK) and preliminary efficacy of HGS-ETR1 in combination with standard doses of paclitaxel and carboplatin.
Journal ArticleDOI
Phase I study of a fully human monoclonal antibody to the tumor necrosis factor-related apoptosis-inducing ligand death receptor 4 (TRAIL-R1) in subjects with advanced solid malignancies or non-Hodgkin's lymphoma (NHL)
Lyly H. Le,Hal W. Hirte,Sebastien J. Hotte,M. Maclean,A. Iacobucci,A. Corey,N. L. Fox,A. M. Oza +7 more
TL;DR: TRM-1 has been well tolerated with no clearly attributable toxicities other than 1 case of grade 3 thrombocytopenia thought possibly related and the maximum tolerated dose has not been reached.
Journal ArticleDOI
Phase I and pharmacokinetic study of HGS-ETR2, a human monoclonal antibody to TRAIL R2, in patients with advanced solid malignancies
Simon Pacey,Ruth Plummer,Gerhardt Attard,C. Bale,A. H. Calvert,Sarah P. Blagden,N. L. Fox,A. Corey,J.S. de Bono +8 more
TL;DR: It is shown that human tumor xenograft models show tumor regression in response to HGS-ETR2 at doses of 2.5 mg/kg or lower, and one subject with hepatocellular carcinoma and extensive hepatic metastases experienced grade 3 tran...